Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
rRgD4KFAK4acZWbr